Safety Study of Olopatadine Nasal Spray
NCT00578331
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
890
Enrollment
INDUSTRY
Sponsor class
Conditions
Perennial Allergic Rhinitis
Interventions
DRUG:
Olopatadine 0.6% nasal spray
DRUG:
Placebo Nasal Spray
Sponsor
Alcon Research